Skip to main content

Pramipexole for Parkinson`s Disease returns to Boehringer Ingelheim`s product portfolio

Pressmeddelande   •   Okt 16, 2004 00:00 CEST

Seamless transition of Parkinson`s Disease drug to its discoverer

16 October 2004
For medical media, outside the US only
Ingelheim/Germany, Cannes/France, 15 October 2004 - Boehringer Ingelheim today announced the return of pramipexole (Mirapex®/ Mirapexin®) to the company’s portfolio of branded pharmaceutical products.

Mirapex® was discovered and pre-clinically developed by Boehringer Ingelheim for the symptomatic treatment of Parkinson’s Disease. Clinical development was then shared between Boehringer Ingelheim and Pharmacia Corporation, now part of Pfizer Inc.

Upon completion of the 2003 acquisition of Pharmacia Corporation, Pfizer Inc agreed to transfer its marketing rights to Mirapex® back to the discoverer Boehringer Ingelheim.

Boehringer Ingelheim now assumes full responsibility for development, global manufacture, marketing and distribution of pramipexole worldwide outside the US.

In the US, Boehringer Ingelheim Pharmaceuticals Inc. has retrieved the marketing authorization of pramipexole (Mirapex®) from Pfizer, Inc already in January 2004. For the time being, Boehringer Ingelheim and Pfizer co-promote Mirapex® for Parkinson’s Disease in the US.

“Pramipexole is a well-established product for the treatment of Parkinson`s Disease which we are developing further due to its potency in other indications, such as Restless Legs Syndrome.” said Dr Alessandro Banchi, Chairman of Boehringer Ingelheim’s Board of Managing Directors. “We assure every patient and customer that they can rely on the first class service, which Boehringer Ingelheim has always provided and a seamless and undisturbed transition of the drug.”

Both companies are working closely together during the transition period to market the drug in the US. With expected sales of approximately € 330 million in 2004, pramipexole is the leading dopamine agonist worldwide.

Pramipexole is approved for the treatment of the signs and symptoms of idiopathic Parkinson’s Disease, as monotherapy (without levodopa) or in combination with levodopa. The approval applies for treatment over the course of the disease through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur.

Boehringer Ingelheim is currently conducting a broad clinical development programme for assessing the therapeutic potential of pramipexole for the indication of Restless Legs Syndrome.

Parkinson’s Disease
Parkinson’s Disease affects approximately one percent of people over age 60, causing tremor, muscle rigidity, slowed motion, shuffling gait and a loss of facial expression. Approximately 15 percent of patients develop PD before the age of 50. All of these effects vary from patient to patient, but worsen over time. PD is the second most common chronic neurological disorder in older adults after Alzheimer’s.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2003, Boehringer Ingelheim posted net sales of 7.4 billion euro while spending more than one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Boehringer Ingelheim GmbH
Corporate Division Communications
Julia Meyer-Kleinmann
55216 Ingelheim am Rhein
Phone: +49/6132/77 82 71
Fax: +49/6132/77 66 01